Adolor Corporation to Present at the UBS Global Life Sciences Conference
September 21 2009 - 4:28PM
Business Wire
Adolor Corporation (NasdaqGM:ADLR) today announced that
management will present at the UBS Global Life Sciences Conference
on Wednesday, September 23, 2009 at 4:00 P.M. Eastern Time. The
conference is being held at the Grand Hyatt, New York, New
York.
Adolor’s presentation will be webcast live for investors through
www.adolor.com and available for a period of one week following the
conference.
About Adolor Corporation
Adolor Corporation is a biopharmaceutical company specializing
in the discovery, development and commercialization of novel
prescription pain management products.
Adolor’s first approved product in the United States is ENTEREG®
(alvimopan), which is indicated to accelerate the time to upper and
lower gastrointestinal recovery following partial large or small
bowel resection surgery with primary anastomosis. ENTEREG is
available for short-term use in hospitals registered under the
E.A.S.E.™ Program. For more information on ENTEREG, including its
full prescribing information, visit www.ENTEREG.com. In
collaboration with GlaxoSmithKline (GSK), the Company launched
ENTEREG in mid-2008.
The Company’s research and development pipeline includes: two
novel delta opioid receptor agonists, currently in mid-stage
clinical development in collaboration with Pfizer Inc. for chronic
pain; a peripheral mu opioid receptor antagonist entering
development for chronic opioid bowel dysfunction (OBD); and several
opioid and non-opioid discovery programs.
For more information, visit www.adolor.com.
Adolor Corp. (MM) (NASDAQ:ADLR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adolor Corp. (MM) (NASDAQ:ADLR)
Historical Stock Chart
From Jul 2023 to Jul 2024